Payment overview · 2025
General Payments
$1,683.26
55 reported records · 15 companies
Healthcare provider profile · identity verified
Krishna R. Singh, MD
Allopathic & Osteopathic Physicians|Family Medicine · SHREVEPORT, LA · NPI 1982713657
Verified facts
What the public records show
CMS Open Payments records show Krishna R. Singh, MD received $1,683.26 in general payments during 2025 across 55 reported records.
AstraZeneca Pharmaceuticals LP accounted for 26.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Ozempic, Rexulti, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Vraylar by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 214 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Symbicort by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 457 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 154 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rexulti by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 134 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $440.24 | 26.1% | 12 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $411.56 | 24.4% | 16 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $191.32 | 11.4% | 6 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $125.00 | 7.4% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $122.47 | 7.3% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $85.41 | 5.1% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $74.29 | 4.4% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $73.03 | 4.3% | 4 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $46.74 | 2.8% | 2 | 2025 |
| Alpha Cognition USA, Inc. | Unresolved — no canonical attribution shown | $24.00 | 1.4% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $22.19 | 1.3% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $19.00 | 1.1% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $18.92 | 1.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.72 | 0.9% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $14.37 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,683.26 | 55 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DALVANCE Normalized: dalvance |
Drug | ABBVIE INC. | $274.90 | 13 | 2025 |
Source payment records
|
|||||
| AVYCAZ Normalized: avycaz |
Drug | ABBVIE INC. | $241.95 | 8 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $191.32 | 6 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $122.47 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $106.43 | 6 | 2025 |
Source payment records
|
|||||
| TEFLARO Normalized: teflaro |
Drug | ABBVIE INC. | $86.72 | 6 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $85.41 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $83.81 | 4 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $74.29 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $73.03 | 4 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $46.74 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $27.03 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $24.11 | 5 | 2025 |
Source payment records
|
|||||
| Zunveyl Normalized: zunveyl |
Drug | Alpha Cognition USA, Inc. | $24.00 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $22.19 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $22.19 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $19.00 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $18.92 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.72 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $14.37 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $11.66 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 214 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 59 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 134 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 100 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
62 | 15 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
214 | 32 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
457 | 51 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
100 | 30 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
154 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
59 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
58 | 11 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
76 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
134 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 980 | 147 |
| Amlodipine Besylate | Amlodipine Besylate | 823 | 152 |
| Gabapentin | Gabapentin | 604 | 109 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 551 | 104 |
| Levothyroxine Sodium | Levothyroxine Sodium | 532 | 68 |
| Losartan Potassium | Losartan Potassium | 520 | 107 |
| Eliquis | Apixaban | 457 | 51 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 446 | 114 |
| Pantoprazole Sodium | Pantoprazole Sodium | 438 | 103 |
| Furosemide | Furosemide | 412 | 78 |
| Potassium Chloride | Potassium Chloride | 387 | 66 |
| Omeprazole | Omeprazole | 363 | 64 |
| Metoprolol Tartrate | Metoprolol Tartrate | 351 | 64 |
| Metformin Hcl | Metformin Hcl | 325 | 52 |
| Alprazolam | Alprazolam | 313 | 42 |
| Carvedilol | Carvedilol | 307 | 62 |
| Tamsulosin Hcl | Tamsulosin Hcl | 296 | 57 |
| Clopidogrel | Clopidogrel Bisulfate | 289 | 58 |
| Famotidine | Famotidine | 262 | 27 |
| Sertraline Hcl | Sertraline Hcl | 255 | 39 |
| Lisinopril | Lisinopril | 252 | 54 |
| Escitalopram Oxalate | Escitalopram Oxalate | 229 | 38 |
| Gemtesa | Vibegron | 221 | 13 |
| Bumetanide | Bumetanide | 220 | 28 |
| Farxiga | Dapagliflozin Propanediol | 214 | 32 |
| Levetiracetam | Levetiracetam | 211 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 199 | 44 |
| Trazodone Hcl | Trazodone Hcl | 194 | 33 |
| Nifedipine Er | Nifedipine | 191 | 39 |
| Metoprolol Succinate | Metoprolol Succinate | 183 | 46 |
| Memantine Hcl | Memantine Hcl | 180 | 20 |
| Xarelto | Rivaroxaban | 175 | 16 |
| Montelukast Sodium | Montelukast Sodium | 172 | 27 |
| Hydrochlorothiazide | Hydrochlorothiazide | 170 | 30 |
| Duloxetine Hcl | Duloxetine Hcl | 166 | 23 |
| Donepezil Hcl | Donepezil Hcl | 165 | 30 |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 159 | suppressed |
| Finasteride | Finasteride | 154 | 19 |
| Jardiance | Empagliflozin | 154 | 28 |
| Quetiapine Fumarate | Quetiapine Fumarate | 154 | 23 |
| Clonidine Hcl | Clonidine Hcl | 152 | 30 |
| Pravastatin Sodium | Pravastatin Sodium | 152 | 28 |
| Meloxicam | Meloxicam | 149 | 39 |
| Ozempic | Semaglutide | 134 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 133 | 27 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 127 | 36 |
| Allopurinol | Allopurinol | 122 | 26 |
| Mirtazapine | Mirtazapine | 119 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 115 | 17 |
| Spironolactone | Spironolactone | 112 | 27 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 107 | 19 |
| Sucralfate | Sucralfate | 105 | 18 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 104 | 20 |
| Risperidone | Risperidone | 101 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 100 | 30 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 98 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 96 | 19 |
| Januvia | Sitagliptin Phosphate | 91 | 14 |
| Tramadol Hcl | Tramadol Hcl | 91 | 31 |
| Prednisone | Prednisone | 90 | 30 |
| Lactulose | Lactulose | 89 | 17 |
| Valsartan | Valsartan | 86 | 16 |
| Simvastatin | Simvastatin | 85 | 24 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 81 | 13 |
| Buspirone Hcl | Buspirone Hcl | 80 | 18 |
| Azithromycin | Azithromycin | 78 | 68 |
| Entresto | Sacubitril/Valsartan | 76 | 20 |
| Ezetimibe | Ezetimibe | 76 | 19 |
| Atenolol | Atenolol | 74 | 13 |
| Metformin Hcl Er | Metformin Hcl | 73 | 17 |
| Baclofen | Baclofen | 70 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 69 | suppressed |
| Pregabalin | Pregabalin | 66 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 65 | 12 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 64 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 64 | suppressed |
| Ibuprofen | Ibuprofen | 62 | 14 |
| Levofloxacin | Levofloxacin | 62 | 58 |
| Linzess | Linaclotide | 62 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 62 | 16 |
| Glipizide | Glipizide | 61 | 15 |
| Clonazepam | Clonazepam | 60 | 13 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 60 | 26 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 59 | suppressed |
| Mounjaro | Tirzepatide | 59 | 11 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 59 | suppressed |
| Trulicity | Dulaglutide | 58 | 11 |
| Digoxin | Digoxin | 56 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 55 | 21 |
| Lamotrigine | Lamotrigine | 55 | suppressed |
| Methocarbamol | Methocarbamol | 54 | 18 |
| Ondansetron Hcl | Ondansetron Hcl | 53 | 22 |
| Divalproex Sodium | Divalproex Sodium | 51 | suppressed |
| Myrbetriq | Mirabegron | 50 | suppressed |
| Lorazepam | Lorazepam | 49 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 47 | suppressed |
| Glimepiride | Glimepiride | 47 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 46 | 44 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 46 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 46 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 45 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 45 | 18 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 44 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 44 | 12 |
| Celecoxib | Celecoxib | 43 | 13 |
| Latanoprost | Latanoprost | 43 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 43 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 43 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 42 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 41 | suppressed |
| Rivastigmine | Rivastigmine | 40 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 39 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 37 | 17 |
| Olanzapine | Olanzapine | 37 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 36 | 31 |
| Doxazosin Mesylate | Doxazosin Mesylate | 36 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 35 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 35 | suppressed |
| Calcitriol | Calcitriol | 34 | suppressed |
| Clonidine | Clonidine | 34 | suppressed |
| Fluconazole | Fluconazole | 32 | 26 |
| Insulin Aspart Flexpen | Insulin Aspart | 32 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 32 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 31 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 31 | 25 |
| Ingrezza | Valbenazine Tosylate | 31 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 31 | 18 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 30 | suppressed |
| Cephalexin | Cephalexin | 29 | 25 |
| Diclofenac Sodium | Diclofenac Sodium | 29 | suppressed |
| Phenobarbital | Phenobarbital | 29 | suppressed |
| Topiramate | Topiramate | 29 | suppressed |
| Novolog Flexpen | Insulin Aspart | 28 | 12 |
| Ranolazine Er | Ranolazine | 28 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 27 | suppressed |
| Colchicine | Colchicine | 27 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 27 | suppressed |
| Methadone Hcl | Methadone Hcl | 27 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 27 | suppressed |
| Repatha Sureclick | Evolocumab | 27 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Nystatin | Nystatin | 26 | 13 |
| Tolterodine Tartrate | Tolterodine Tartrate | 26 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 25 | suppressed |
| Letrozole | Letrozole | 25 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 25 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 24 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 24 | 11 |
| Lovastatin | Lovastatin | 24 | suppressed |
| Methylprednisolone | Methylprednisolone | 24 | 22 |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Carbamazepine | Carbamazepine | 23 | suppressed |
| Scopolamine | Scopolamine | 23 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 23 | suppressed |
| Humalog | Insulin Lispro | 21 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 21 | suppressed |
| Vraylar | Cariprazine Hcl | 21 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 20 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 20 | suppressed |
| Levemir Flexpen | Insulin Detemir | 20 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 20 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 20 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 19 | 12 |
| Lacosamide | Lacosamide | 19 | suppressed |
| Amoxicillin | Amoxicillin | 18 | 13 |
| Anastrozole | Anastrozole | 18 | suppressed |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 18 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 18 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 18 | 16 |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Movantik | Naloxegol Oxalate | 18 | suppressed |
| Diazepam | Diazepam | 17 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 17 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 14 |
| Promethazine Hcl | Promethazine Hcl | 17 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 16 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 16 | suppressed |
| Levemir | Insulin Detemir | 16 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 16 | suppressed |
| Roflumilast | Roflumilast | 16 | suppressed |
| Temazepam | Temazepam | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 15 | 12 |
| Estradiol | Estradiol | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | 13 |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Rexulti | Brexpiprazole | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 15 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Ethosuximide | Ethosuximide | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Insulin Lispro | Insulin Lispro | 13 | suppressed |
| Livalo | Pitavastatin Calcium | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | 12 |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 12 | suppressed |
| Metolazone | Metolazone | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 12 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 12 | suppressed |
| Anagrelide Hcl | Anagrelide Hcl | 11 | suppressed |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 11 | suppressed |
| Nabumetone | Nabumetone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,683.26 · 55 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, AVYCAZ, BREZTRI, COBENFY, DALVANCE, FARXIGA, FASENRA, IBSRELA, Kerendia, LEQVIO, MOUNJARO, Ozempic, QULIPTA, REPATHA, REXULTI, TEFLARO, TRELEGY ELLIPTA, UBRELVY, VERQUVO, VOQUEZNA, Veozah, ZEPBOUND, Zunveyl | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error